Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Overcoming the biotech investment paradox

By Haydn Boehm | December 27, 2022

invest

[Photo by Monstera via Pexels]

As COVID wreaked havoc on our markets, biotech appeared to be an outlier, not just weathering the storm but emerging stronger than ever with record investments and valuations. Then reality struck. Assets lingered in the early stages. Commercialized products underperformed. Valuations tumbled. Now, a new normal has arrived, presenting a biotech investment paradox to small and midsize companies — how to deliver promising innovations and low-risk investment options to an increasingly wary market.

Even before the pandemic, small to midsize biotechs were gaining ground, thanks in part to their nimbler adoption of new technologies, faster-paced innovation and partnerships with larger companies hoping to overcome internal stagnation and offset impending patent expirations.

EY reports that new molecular entity (NME) approvals attributed to small biotechs with revenues less than $1 billion were around 10% in 2017. By 2021, that reached 30%. McKinsey & Company reports the pace of innovation has also been increasing, with assets passing through early phase trials up to 50% faster than before, though the development of later stage assets has remained flat.

The downturn spurring hesitancy

The eventual market downturn meant biotechs must either travel the unfamiliar path toward commercialization or prove their worth to increasingly trepidatious investors. Today, Big Pharmas are more measured in their risk-taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships. Investors are less willing to jump in early, often delaying their moves until after Phase 2 or 3 trials, demanding data-backed validation and setting strict milestones. Biotechs with early-phase assets or platforms no longer have an easy path to IPO and, instead, face a growing demand to differentiate themselves in a sea of similar start-ups.

Many companies are waiting out the downturn, staying private for as long as possible while stretching budgets and streamlining operations; some are even tempering R&D efforts or joining scores of competitors focused on indications with well-validated assays and endpoints — a strategy that some fear could stifle innovation in the long-run.

For many biotechs, delivering rapid innovation with good returns seems insurmountable when faced with myriad other challenges, such as fewer late-stage assets, heightened consumer expectations, new pricing legislation and increased cyber threats. As a result, companies must adjust their strategic priorities to deliver on the market’s demands. Deloitte recently reported on the key priorities for biopharmas to stay competitive. Aside from expanding global reach, the top priorities include strengthening R&D and improving digital and IT technologies.

How a scalable R&D platform supports biotech investment

As biotechs grow, the systems that sufficed for small teams typically don’t scale well and instead start hindering progress. As a result, companies can either build an end-to-end cheminformatics discovery platform themselves or find a partner whose open platform can help them seamlessly integrate the diverse applications, workflows and data they need.

Adopting a flexible, scalable R&D platform reduces the onus of integrating internal systems, such as those used for study capture, compound registration, inventory management, assay design and data management. Companies can then focus their time, money and expertise on what matters most — the science that will help them make better therapies faster and increase their chances of success.

Support transformational change

Biotechs must analyze their R&D workflows and identify changes that will impact a few teams’ processes and improve outcomes across their organizations.

Many drug-discovery companies should prioritize biotech investment that involves technology that frees decision-makers to focus on science, not cumbersome processes. Unfortunately, several obstacles often stand in the way of this goal, including disconnected R&D systems, workflow complexity, compromised data value, high failure rates in small molecule drug discovery, and structural complexity and diversification in biologics discovery. Nevertheless, companies can overcome these obstacles through biotech investment in tools that streamline end-to-end workflows, accelerate research, facilitate collaboration and improve decision-making.

Creating a strong data foundation

Big data has become synonymous with big possibilities. Companies across industries are looking to both gain competitive advantages and generate revenues. They’re also pouring tens of millions of dollars into AI initiatives each year. Unfortunately, many biopharmas face a harsh reality — their data are ill-suited for utilization in AI for various reasons, such as poor access, lack of standardization, inefficient annotation, questionable integrity and limited traceability. In a recent survey of biopharma and medtech companies, Deloitte found that nearly 30% of life science leaders admit that data struggles negatively impact their AI initiatives.

Biotechs must create a strong data foundation to benefit from AI and machine learning. That means capturing clean and trustworthy research data, removing data silos and provisioning model-quality data.

Tackling regulatory readiness

An increasingly common regulatory issue facing leaders is data integrity, which can greatly impact a drug’s safety, efficacy and quality. Such violations have become more common as labs shift from paper to electronic record keeping, with the FDA releasing industry guidance. While egregious offenses like falsifying data make headlines, the FDA’s transparent sharing of warning letters highlights many less-headline-grabbing offenses, such as data loss, missing metadata, uninvestigated sample elimination or reprocessing, security issues and inadequate audits.

Luckily, labs can choose solutions that help mitigate the risk of violations, such as automatically recording experiment details and audit trails, requiring signatures and restricting data manipulation or deletion. Upholding the integrity and security of data generated throughout a product’s entire lifecycle better ensures regulatory readiness while enabling that product to become more compelling to investors.

Haydn Boehm

Haydn Boehm

While biotechs face new challenges, history shows the industry has always bounced back. McKinsey projects the market will rebound as long as companies carefully focus their talent, budgets and don’t lose sight of the fundamentals — increasing regulatory clarity and commercial viability for innovative therapies addressing unmet needs.

Haydn Boehm is director of product marketing at Dotmatics, a leader in R&D scientific software connecting science, data, and decision-making. Its enterprise R&D platform and scientists’ favorite applications drive efficiency and accelerate innovation.


Filed Under: Drug Discovery and Development
Tagged With: biotech investment
 

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE